Genentech, Inc.

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Paul Goldsmith

Bing-Yan Zhu

Daniel P Sutherlin

Alan G Olivero

Adrian Folkes

Steven Huy Do

Aleksandr Kolesnikov

Steven T Staben

Michael Siu

Richard A Goldsmith

Tim Heffron

Tracy Bayliss

Neil Pegg

Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use

Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulene compounds

Growing community of inventors

Basel, Switzerland

Paul Goldsmith